Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective Reference 24 needs to be amended to 25 The 12-week study needs to be corrected to 8-week study
Corrected text:
This study is the first to compare two LAMA/LABA dual therapies using direct head-to-head data from a randomized, 8-week study [25] , which is the most reliable set of data to include within a cost-effectiveness model [25] . 
